Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
Nature Medicine2008Vol. 14(12), pp. 1351–1356
Citations Over TimeTop 1% of 2008 papers
Jeffrey A. Engelman, Liang Chen, Xiaohong Tan, Katherine Crosby, Alexander R. Guimarães, Rabi Upadhyay, Michel Maira, Kate McNamara, Samanthi A. Perera, Youngchul Song, Lucian R. Chirieac, Ramneet Kaur, Angela Lightbown, Jessica Simendinger, Timothy Li, Robert F. Padera, Carlos Garcı́a-Echeverrı́a, Ralph Weissleder, Umar Mahmood, Lewis C. Cantley, Kwok‐Kin Wong
Related Papers
- → Targeting Class IA PI3K Isoforms Selectively Impairs Cell Growth, Survival, and Migration in Glioblastoma(2014)41 cited
- → Development of PI3Kα inhibitors for tumor therapy(2022)12 cited
- → Recent Development in Targeting PI3K-Akt-mTOR Signaling for Anticancer Therapeutic Strategies(2013)29 cited
- → Abstract 875: Marked in vivo efficacy of combined BCLXL and MEK inhibition in KRAS mutant cancers revealed by a pooled shRNA-drug screen for genes that are “synthetically lethal” with MEK inhibitors(2012)
- → The RAF/MEK clamp VS-6766 shows strong anti-tumor activity across multiple MAPK pathway alterations, with a preferential effect on KRAS G12V(2022)